Acorda Therapeutics (FRA:CDG) Short Percentage of Float

View and export this data going back to 2006. Start your Free Trial

What is Acorda Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Acorda Therapeutics's Short Percentage of Float

For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acorda Therapeutics's Short Percentage of Float Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Acorda Therapeutics's Short Percentage of Float falls into.

Acorda Therapeutics (FRA:CDG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acorda Therapeutics Inc (FRA:CDG) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

ACOR:USA

Address

2 Blue Hill Plaza, 3rd Floor, Pearl River, New York, NY, USA, 10965

Website

https://www.acorda.com

Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.

Acorda Therapeutics (FRA:CDG) Headlines

No Headlines